There is an important distinction between a treatment being cost-effective and it being affordable for the NHS as illustrated by the example of tirzepatide. NICE has concluded that tirzepatide is cost-effective in appropriately selected patients because of the health gains it delivers through reductions in obesity-related disease and its complications. However, the overall budget impact is a separate question. When millions of people could potentially be eligible for treatment, even a cost-effective intervention can create major financial pressures for the NHS. We are still at a relatively early stage of implementation, yet tirzepatide has already become one of the NHS's highest-cost medicines. If access expands in line with NICE guidance over the coming years, expenditure will increase substantially unless drug prices fall significantly, prescribing criteria change or treatment strategies evolve. Another important issue is that we still have key unanswered questions about long-ter...
Meningococcal group B (MenB) infections are rare but can have devastating consequences. The decision to offer a targeted two-dose vaccination programme to Year 13 students and young people entering university or residential further education reflects concerns about recent outbreaks of meningococcal disease and the higher risk of transmission when large numbers of young adults mix closely for the first time in shared accommodation. The MenB vaccine has a well-established safety record, and evidence from the UK infant immunisation programme has shown substantial reductions in disease among vaccinated children. A targeted programme for those entering higher-risk settings is therefore a reasonable precautionary measure while further evidence is gathered on whether the recent increase in clusters represents a temporary fluctuation in disease patterns or a more sustained change in the epidemiology of MenB infection. The success of the programme will depend on achieving high uptake and ensuri...